Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer.

Journal for immunotherapy of cancer·2025

Same author

MHC2-SCALE enhances identification of immunogenic neoantigens.

iScience·2025

Same author

RNA neoantigen vaccines prime long-lived CD8<sup>+</sup> T cells in pancreatic cancer.

Nature·2025

Same author

IL-27 elicits a cytotoxic CD8<sup>+</sup> T cell program to enforce tumour control.

Nature·2025

Same author

Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.

Cancer immunology research·2025

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Harnessing dendritic cells for immunotherapy.

Lélia Delamarre¹, Ira Mellman

¹Genentech, 1 DNA Way, South San Francisco, CA 94080, United States. delamarre.lelia@gene.com

Seminars in Immunology

|March 8, 2011

Summary

This summary is machine-generated.

Dendritic cells (DCs) are key antigen-presenting cells that initiate adaptive immunity or tolerance. Different DC subsets and antigen acquisition contexts determine the immune response outcome, guiding immunotherapy design.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Related Experiment Videos

Last Updated: Jun 3, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Area of Science:

Immunology
Cell Biology

Background:

Dendritic cells (DCs) are crucial antigen-presenting cells initiating adaptive immune responses.
DCs differentiate between self and foreign antigens using microbial sensors, inducing immunity or tolerance based on environmental signals.

Purpose of the Study:

To discuss the specialized functions of distinct dendritic cell subsets.
To explore how antigen acquisition context and DC subsets influence immune response outcomes.
To provide insights into designing immunotherapy based on DC functions.

Main Methods:

Review of dendritic cell subset features.
Analysis of antigen handling for MHCI and MHCII presentation.
Examination of regulatory signals impacting DC function.

Main Results:

Distinct DC subsets possess specialized functions influencing adaptive immunity.
Antigen presentation by DCs is context-dependent, affecting immune response type.
DC subset behavior and regulation offer therapeutic strategies for immunotherapy.

Conclusions:

Understanding dendritic cell subsets and their regulation is vital for predicting and manipulating immune responses.
The context of antigen acquisition and the specific DC subset involved are critical determinants of immune outcomes.
Dendritic cell biology provides a foundation for developing targeted immunotherapies.